

CITATION REPORT

List of articles citing

Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting

DOI: 10.1016/j.transproceed.2013.02.021
Transplantation Proceedings, 2013, 45, 1273-5.

Source: <https://exaly.com/paper-pdf/55744587/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
24	Update on the clinical utility of once-daily tacrolimus in the management of transplantation. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 1183-94	4.4	17
23	Prevention of organ rejection in renal and liver transplantation with extended release tacrolimus. <i>Transplant Research and Risk Management</i> , 2014 , 55	1.1	
22	A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. <i>Transplant International</i> , 2014 , 27, 1294-302	3	12
21	Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. <i>Genetics and Molecular Research</i> , 2015 , 14, 15148-57	1.2	7
20	Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2015 , 15, 1267-82	8.7	50
19	Single Center Experiences of Conversion from Twice-daily Tacrolimus (Prograf) to Once-daily Tacrolimus (Advagraf) in Stable Liver Transplant Recipients. <i>The Journal of the Korean Society for Transplantation</i> , 2016 , 30, 77	0.3	
18	LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. <i>Transplant International</i> , 2016 , 29, 603-11	3	17
17	Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. <i>Liver Transplantation</i> , 2016 , 22, 1391-400	4.5	14
16	Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. <i>Drugs - Real World Outcomes</i> , 2016 , 3, 61-68	2.2	5
15	Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study. <i>Clinical Transplantation</i> , 2018 , 32, e13376	3.8	2
14	Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. <i>Transplantation</i> , 2019 , 103, 470-480	1.8	12
13	Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study. <i>Transplantation</i> , 2019 , 103, 1844-1862	1.8	7
12	Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO): Study protocol for an investigator initiated, non-interventional prospective study. <i>Medicine (United States)</i> , 2020 , 99, e22180	1.8	
11	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021 , 9, 135	2.9	14
10	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. <i>Antioxidants</i> , 2021 , 10,	7.1	26
9	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2345-2353	4.5	17
8	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2021 ,	3.4	1

7	HCC and Molecular Targeting Therapies: Back to the Future. <i>Biomedicines</i> , 2021 , 9,	4.8	2
6	Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study. <i>Annals of Transplantation</i> , 2018 , 23, 713-720	1.4	3
5	Efficacy and safety of prolonged-release versus immediate-release tacrolimus in de novo liver transplant recipients in South Korea: a randomized open-label phase 4 study (MAPLE). <i>Korean Journal of Transplantation</i> , 2019 , 33, 20	0.2	
4	Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study. <i>Annals of Transplantation</i> , 2019 , 24, 36-44	1.4	2
3	Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.. <i>PLoS ONE</i> , 2022 , 17, e0265178	3.7	
2	Psychometric Properties of the BAASIS: A Meta-analysis of Individual Participant Data. Publish Ahead of Print,		0
1	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. 2023 , 11, 468		3